Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Inclusion criteria for patients with acromegaly:

- Male or female patients between 18 and 80 years

- Patients with acromegaly due to a pituitary adenoma with elevated GH and IGF-1
concentrations

Exclusion criteria for patients with acromegaly:

- Patients with compression of the optic chiasm causing any visual field defect

- Specific criteria apply for patients who have received certain types of therapies
such as radiotherapies, surgeries, chemo- or immunotherapies in the months prior to
study start

- Female patients who are pregnant or lactating

Inclusion criteria for patients with carcinoid disease:

- Male or female patients aged ≥18 years

- Patients with histologically confirmed, metastatic carcinoid tumors of the digestive
system

- Patients with elevation of chromogranin-A (CgA) and/or serotonin

- Patients who are not adequately controlled by somatostatin analogues

Exclusion criteria for patients with carcinoid disease:

- Specific criteria apply for patients who have received certain types of therapies
such as radiotherapies, surgeries, chemo- or immunotherapies in the months prior to
study start

- Female patients who are pregnant or lactating

Other protocol-defined in- and exclusion criteria may apply.